.jpg)
Recent from talks
Hans Clevers
Knowledge base stats:
Talk channels stats:
Members stats:
Hans Clevers
Johannes (Hans) Carolus Clevers (born 27 March 1957) is a Dutch molecular geneticist, cell biologist and stem cell researcher. He became the Head of Pharma, Research and Early Development, and a member of the Corporate Executive Committee, of the Swiss healthcare company Roche in 2022. Previously, he headed a research group at the Hubrecht Institute for Developmental Biology and Stem Cell Research and at the Princess Máxima Center; he remained as an advisor and guest scientist or visiting researcher to both groups. He is also a Professor in Molecular Genetics at Utrecht University.
Hans Clevers was born in Eindhoven, the Netherlands in 1957. He began studying biology at Utrecht University in 1975, but also started taking medicine in 1978, in part due to his interest and in part because his friends and brothers were in the medical profession. He spent 1 year in Nairobi, Kenya, and half a year at the National Institutes of Health in Bethesda, United States, for biology rotations. He received a Doctoraal (equivalent to an MSc) in Biology in 1982 and an Artsexamen (equivalent to an MD) in 1984. Mostly because of his research background, Clevers was selected for a training position in paediatrics, and then went to pursue a PhD in 1985, under the supervision of Rudy Ballieux. He obtained his PhD 1 year later.
After his PhD, Clevers went to the Dana–Farber Cancer Institute as a postdoctoral researcher at Cox Terhorst's group. In 1989, he returned to the Netherlands, joining his alma mater, Utrecht University, as an assistant professor at the Department of Clinical Immunology.
In 1991, Clevers became a professor and the chair of the Department of Immunology at Utrecht University. He moved to the University Medical Center Utrecht in 2002 as a professor in molecular genetics, and started his lab at the Hubrecht Institute for Developmental Biology and Stem Cell Research (Hubrecht Institute). At the same time, he took up the position of Director of the Hubrecht Institute.
In March 2012, Clevers was elected the president of the Royal Netherlands Academy of Arts and Sciences, succeeding Robbert Dijkgraaf. His term concluded in 2015, and he started another lab at the Princess Máxima Center, focusing on childhood cancer, and became the Director Research and Chief Scientific Officer there until 2019.
Clevers left University Medical Center Utrecht and was appointed Professor in Molecular Genetics at Utrecht University in 2020.
In 2022, Clevers joined the Swiss healthcare company Roche as its Head of Pharma, Research and Early Development and a member of its Corporate Executive Committee. He remains an advisor and guest scientist or visiting researcher to his research groups at the Princess Máxima Center and Hubrecht Institute.
Since 2017, Clevers is an investigator at the Oncode Institute in Utrecht.
Hub AI
Hans Clevers AI simulator
(@Hans Clevers_simulator)
Hans Clevers
Johannes (Hans) Carolus Clevers (born 27 March 1957) is a Dutch molecular geneticist, cell biologist and stem cell researcher. He became the Head of Pharma, Research and Early Development, and a member of the Corporate Executive Committee, of the Swiss healthcare company Roche in 2022. Previously, he headed a research group at the Hubrecht Institute for Developmental Biology and Stem Cell Research and at the Princess Máxima Center; he remained as an advisor and guest scientist or visiting researcher to both groups. He is also a Professor in Molecular Genetics at Utrecht University.
Hans Clevers was born in Eindhoven, the Netherlands in 1957. He began studying biology at Utrecht University in 1975, but also started taking medicine in 1978, in part due to his interest and in part because his friends and brothers were in the medical profession. He spent 1 year in Nairobi, Kenya, and half a year at the National Institutes of Health in Bethesda, United States, for biology rotations. He received a Doctoraal (equivalent to an MSc) in Biology in 1982 and an Artsexamen (equivalent to an MD) in 1984. Mostly because of his research background, Clevers was selected for a training position in paediatrics, and then went to pursue a PhD in 1985, under the supervision of Rudy Ballieux. He obtained his PhD 1 year later.
After his PhD, Clevers went to the Dana–Farber Cancer Institute as a postdoctoral researcher at Cox Terhorst's group. In 1989, he returned to the Netherlands, joining his alma mater, Utrecht University, as an assistant professor at the Department of Clinical Immunology.
In 1991, Clevers became a professor and the chair of the Department of Immunology at Utrecht University. He moved to the University Medical Center Utrecht in 2002 as a professor in molecular genetics, and started his lab at the Hubrecht Institute for Developmental Biology and Stem Cell Research (Hubrecht Institute). At the same time, he took up the position of Director of the Hubrecht Institute.
In March 2012, Clevers was elected the president of the Royal Netherlands Academy of Arts and Sciences, succeeding Robbert Dijkgraaf. His term concluded in 2015, and he started another lab at the Princess Máxima Center, focusing on childhood cancer, and became the Director Research and Chief Scientific Officer there until 2019.
Clevers left University Medical Center Utrecht and was appointed Professor in Molecular Genetics at Utrecht University in 2020.
In 2022, Clevers joined the Swiss healthcare company Roche as its Head of Pharma, Research and Early Development and a member of its Corporate Executive Committee. He remains an advisor and guest scientist or visiting researcher to his research groups at the Princess Máxima Center and Hubrecht Institute.
Since 2017, Clevers is an investigator at the Oncode Institute in Utrecht.
Recent media